Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable.

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS's Breyanzi is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic.

Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS to Present First Results at ASCO & EHA from Phase 3 COMMANDS Study of Reblozyl in First-Line Treatment.

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACS--Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program.

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation

Bristol Myers' (BMY) idiopathic pulmonary fibrosis drug reduces the rate of lung function decline in a phase II study.

Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ATS2023--Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis.

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

Bristol Myers Squibb's strong pipeline is yielding new approvals that are helping replace older products. Although the company's revenue has been decreasing in the past few quarters, that should change soon.

1 Dirt Cheap Dividend Stock to Buy in May

Amgen

Cigna

Centene

Gilead Sciences

Labcorp Holdings Inc

Organon & Co

Pfizer

Viatris

The stocks our screen found are cheap, relative to highfliers like Eli Lilly, and many are cheap for a reason.

9 Cheap Healthcare Stocks to Consider

Bristol-Myers Squibb Company (NYSE:BMY ) Bank of America Securities 2023 Health Care Conference May 9, 2023 11:40 AM ET Company Participants Adam Lenkowsky - EVP, Head of Commercial Conference Call Participants Geoff Meacham - Bank of America Geoff Meacham Welcome to the first morning of the BofA Healthcare Conference. My name is Geoff Meacham.

Bristol-Myers Squibb Company (BMY) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #17ICML--BMS to Highlight Diversified Approaches and Commitment to Improving Outcomes at ASCO, EHA and ICML 2023.

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

Bristol-Myers Squibb's stock hasn't been doing well of late, as investors have been discounting it. The company's lack of growth and high debt load hasn't made it an attractive buy.

Is Bristol-Myers Squibb Stock a Buy Now?

Coca-Cola

Verizon

Bristol Myers, Verizon, and Coca-Cola all pay dividends with better yields than the S&P 500. These businesses have solid financials with plenty of room to support their dividend payments.

3 High-Yielding Dividend Stocks That Could Pay You Forever

Bristol-Myers is now in a period of relatively less output from its late-stage pipeline. It's going to acquire businesses and make collaboration deals to ameliorate that.

3 Things About Bristol-Myers Squibb That Smart Investors Know

Eli Lilly

There are often trade-offs to make when selecting passive income stocks. Eli Lilly's next couple of years will see its revenue burgeon by billions.

Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?

Bristol Myers Squibb grew its profits in the first quarter. The company's generous dividend appears to be sustainable.

Should Income Investors Buy This Blue Chip Dividend Stock?

Bristol-Myers Squibb stock delivered a poor performance in 2023 despite solid FY 2022 and Q1 2023 results. The new product portfolio finally showed a sign of living with impressive growth rates.

Bristol-Myers Squibb: Attractive Entry As New Products Sales Accelerate

Broadcom

Dividend stocks to watch in the stock market today.

Best Dividend Stocks To Buy In 2023? 2 To Know

Bristol-Myers Squibb isn't a star-studded growth stock, but its valuation is fair. The next couple of years might be a bit slow for shareholders.

Want Passive Income at a Fair Price? Consider Buying This Dividend Growth Stock

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy.

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference.

Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--FDA Accepts for Priority Review supplemental Biologics License Application and European Medicines Agency Validates Application for Reblozyl.

U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of Overall Response Rate.

Bristol Myers Squibb's TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.

Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales

Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Bristol Myers (BMY) Q1 Earnings: A Look at Key Metrics

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.96 per share a year ago.

News for Bristol-Myers Stock (BMY)